Image For Activity Cover
Treatment and Engagement Strategies for Youth and Young Adults with Opioid Use Disorder (OUD)
J. Craig Allen, MD, FASAM, Medical Director, Rushford, Chief of Psychiatry, Midsta, Assistant Professor of Psychiatry, University of Connecticut School of Medicine, Associate Professor of Psychiatry, Frank H. Netter School of Medicine, Quinnipiac University
Target Audience
This activity is designed to meet the needs of primary care physicians, specialty care physicians, psychiatrists, allied professional staff, program administrators, staff specializing in adolescent services.
Webinar Description
Adolescents and young adults are one-tenth as likely to get appropriate treatment for opioid use disorder (OUD) than those over the age of 25. Medications for opioid use disorder (MOUD), considered first line treatments, decrease the risk of overdose death from 50-80%. Nonetheless, a study recently published in JAMA Pediatrics looked found that less than 2% of adolescents and young adults received one of the three FDA-approved medications. This may be due to lack of education and training for medical providers, lack of clinically appropriate care available in specialty settings or concerns about using these medications with this age group. Today’s webinar will provide education and guidance to interested providers about how to effectively treat and engage adolescents and young adults in opioid use disorder treatment.
Educational Objectives

At the conclusion of this activity, learners should be able to:

  • Identify the major risk factors for developing OUD
  • Examine the evidence supporting MOUD
  • Identify strategies to intervene with youth at risk of developing or having developed OUD
  • Review strategies to engage in OUD treatment
Availability: On-Demand
Expires on 06/11/2023
Cost: FREE
Credit Offered:
1 Attendance Credit
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By